Efficacy and safety of canagliflozin (CANA), an inhibitor of sodium glucose co-transporter 2 (SGLT2), added-on to insulin therapy plus /- oral agents in type 2 diabetes

Detalhes bibliográficos
Principais autores: Matthews, DR, Fulcher, G, Perkovic, V, de Zeeuw, D, Mahaffey, K, Rosenstock, J, Davies, M, Capuano, G, Desai, M, Shaw, W, Vercruysse, F, Meininger, G, Neal, B
Formato: Journal article
Publicado em: 2012